



PROTECT-CH

Prophylactic Therapy in Care Homes Trial

Introduction



**Welcome to
PROTECT-CH Trial!**

**Thank you for your
interest in taking part!**





University of
Nottingham

UK | CHINA | MALAYSIA

PROTECT-CH

Prophylactic Therapy in Care Homes Trial

**This trial is funded by the
National Institute for
Health Research**

FUNDED BY

NIHR | National Institute
for Health Research




University of
Nottingham

UK | CHINA | MALAYSIA

PROTECT-CH

Prophylactic Therapy in Care Homes Trial

**This trial is funded by the
National Institute for
Health Research**



FUNDED BY

NIHR | National Institute
for Health Research



University of
Nottingham

UK | CHINA | MALAYSIA

PROTECT-CH

Prophylactic Therapy in Care Homes Trial

and is being conducted
by the University of Nottingham

FUNDED BY

NIHR | National Institute
for Health Research



University of
Nottingham

UK | CHINA | MALAYSIA

PROTECT-CH

Prophylactic Therapy in Care Homes Trial



and is being conducted
by the University of Nottingham

FUNDED BY


NIHR | National Institute
for Health Research

A large, light green thought bubble with a white crumpled paper texture inside, set against a light blue background. The bubble has a small stem at the bottom.

**What is the
trial about?**





As you know, residents in care homes have a greater risk of infection and death due to COVID-19





This trial will be testing medications to try to...





**Reduce the
number of
residents who
get infected
with COVID-19**



**Reduce the
number of
residents who
get infected
with COVID-19**

AND



**Reduce the
number of
residents who
get infected
with COVID-19**

AND

**Help reduce the
severity of the
disease and
number of
residents who die
from COVID-19**



Government scientific advisors are recommending which treatments they want us to test



A large, light green thought bubble with a white crumpled paper texture inside, set against a dark blue background. The bubble has a small stem at the bottom.

**What does that
mean for my care
home?**



All of your residents who consent to take part in the trial





will be allocated to take either:



**A trial
medication
which aims to
reduce
transmission of
COVID-19
(plus standard care)**





**A trial
medication
which aims to
reduce
transmission of
COVID-19
(plus standard care)**



OR



**A trial
medication
which aims to
reduce
transmission of
COVID-19
(plus standard care)**




OR

**Continue with
standard care
(No trial medication)**





**All residents involved in the trial at
your care home will be allocated to
the same group**





**You will not be able to choose which
group your care home is in
(a computer at the University will
decide at random)**





**You will not be able to choose which
group your care home is in
(a computer at the University will
decide at random)**

**This is the only way we can tell if the
trial medication works or not**





Whichever group your care home is in, it is crucial we receive information from you on the health of your residents





**This will help us to find out whether a
trial medication works and does not
cause side effects**



A large, light green thought bubble with a white crumpled paper texture inside, set against a solid blue background. The bubble has a small stem at the bottom.

**How do residents
sign up to take
part?**




Information about the trial will be given to residents (or their personal legal representative if they lack capacity)





If they agree to take part,
they will be asked to
sign a consent form





**Consent will be obtained virtually
by an external research nurse**





**Residents do not have to take
part in the trial if they do not wish
to**



A large, teal-colored thought bubble with a white, crumpled paper texture inside. The bubble is centered on the page and contains the text 'What does taking part actually involve?'.

**What does taking
part actually
involve?**



1

**After consent has been received,
the resident's GP will then be asked to give
information about the resident's health to ensure
they are eligible to take the medication.**





2

All this information will be checked by a trial doctor (known as Principal Investigator) who will confirm eligibility and prescribe the trial medication as required






3

**You will administer the trial medication as prescribed
& continue to deliver standard care to the resident**

(or just continue delivering standard care- depending on your group)





4

You will be asked to collect information about the resident throughout the trial and will enter it into a secure database





This will include information about:



4

This will include information about:

- **If they have taken the medication**





4

This will include information about:

- **If they have taken the medication**
- **The health of the resident**






4

This will include information about:

- If they have taken the medication
- The health of the resident
- If they test positive for COVID-19






4

This will include information about:

- If they have taken the medication
- The health of the resident
- If they test positive for COVID-19
- If they get admitted to hospital



A large, stylized thought bubble graphic with a green outline and a white crumpled paper texture. It is centered on the page. Inside the bubble, the text "Will we receive trial training?" is written in a bold, black, sans-serif font.

**Will we receive trial
training?**



**Yes - training for all care home staff who are part of this trial will be made available on the trial website:
www.protect-trial.net**





However, please get in touch if you have any questions



protect-trial@nottingham.ac.uk



0115 74 87710

Thank you for your interest in the trial!

PROTECT-CH



Prophylactic Therapy in Care Homes Trial

